ProCE Banner Activity

EMPOWER-Lung 3 Part 1: Patient-Reported Outcomes With First-line Cemiplimab + Chemotherapy + Ipilimumab in Advanced NSCLC

Conference Coverage

In this analysis of the phase III EMPOWER-Lung 3 Part 1 trial, patient-reported outcomes favored first-line cemiplimab plus chemotherapy plus ipilimumab vs chemotherapy alone in patients with advanced NSCLC and PD-L1 expression <50%.

Released: May 13, 2024

Expiration: May 12, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc